Company Filing History:
1 out of 1,745 
1 out of 157 
1 out of 29 Years Active: 2022
Title: Nesrine Aroua: Innovator in Pharmaceutical Compositions for Chemoresistant Acute Myeloid Leukemia
Introduction
Nesrine Aroua is a prominent inventor based in Toulouse, France. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chemoresistant acute myeloid leukemia (AML). Her innovative work has the potential to improve the lives of patients suffering from this challenging condition.
Latest Patents
Nesrine Aroua holds a patent for pharmaceutical compositions aimed at treating chemoresistant acute myeloid leukemia (AML). The invention focuses on a powerful preclinical model that screens in vivo responses to conventional genotoxics, mimicking the chemoresistance and minimal residual disease observed in AML patients post-chemotherapy. The research highlights the cytarabine-resistance mechanism, which involves the CD39-dependent crosstalk between the energetic niche and AML mitochondrial functions through the CD39-P2Y13-cAMP-PKA signaling axis. The patent specifically relates to an inhibitor of this signaling axis for use in treating patients with chemoresistant AML.
Career Highlights
Throughout her career, Nesrine Aroua has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Sante Et De La Recherche Medicale) and the University of Paul Sabatier (Toulouse III). Her work in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Nesrine Aroua has collaborated with notable colleagues, including Jean-Emmanuel Sarry and Christian Recher. These partnerships have enriched her research and expanded the impact of her innovations in the medical field.
Conclusion
Nesrine Aroua is a trailblazer in the development of pharmaceutical solutions for chemoresistant acute myeloid leukemia. Her patent and collaborative efforts reflect her commitment to advancing medical science and improving patient outcomes.